Skip to main content
Top
Published in: World Journal of Urology 5/2009

01-10-2009 | Original Article

[11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

Authors: Ludwig Rinnab, Joerg Simon, Richard E. Hautmann, M. V. Cronauer, Kathrin Hohl, Andreas K. Buck, Sven N. Reske, Felix M. Mottaghy

Published in: World Journal of Urology | Issue 5/2009

Login to get access

Abstract

Objective

To evaluate [11C]choline positron emission tomography/computed tomography ([11C]choline PET/CT) for the detection of a biochemical recurrence of prostate cancer after radical prostatectomy.

Methods

Retrospective analysis of [11C]choline PET/CT performed in 41 consecutive prostate cancer patients with a rising PSA. The mean time to biochemical relapse was 24 months. PSA levels were determined at time of examination, and patients received either a targeted biopsy or surgery. Histopathology reports served as reference for the evaluation of the [11C]choline PET/CT findings.

Results

Mean PSA in [11C]choline PET/CT positive patients was 3.1 ng/ml (median 2.2 ng/ml, range 0.5–11.6 ng/ml) and 0.86 ng/ml in [11C]choline PET/CT negative patients (median 0.83 ng/ml, range 0.41–1.40 ng/ml). Six of 12 patients with PSA < 1.5 ng/ml [11C]choline PET/CT revealed a pathological uptake. Histopathology was positive in 6/12 patients in this group. At PSA levels ranging from 1.5 to 2.5 ng/ml all [11C]choline PET/CT were positive (n = 16), a positive histology was found in 12/16 patients (75%) and at PSA 2.5–5 ng/ml [11C]choline PET/CT was positive in 8/8 patients, confirmed by histology in 7/8 patients. Finally, at PSA higher than 5 ng/ml [11C]choline PET/CT identified 5/5 patients positive all confirmed by histology. The sensitivity of [11C]choline PET/CT for the detection of recurrence at PSA < 2.5 ng/ml was 89% with a positive predictive value of 72%.

Conclusion

[11C]choline PET/CT is useful for re-staging of prostate cancer in patients with rising PSA even at levels below 1.5 ng/ml. Our study confirms results from other published studies on [11C]choline PET/CT in prostate cancer relapse.
Literature
2.
go back to reference Scattoni V, Roscigno M, Raber M, Montorsi F, Da Pozzo L, Guazzoni G et al (2003) Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 44(4):407–414. doi:10.1016/S0302-2838(03)00320-8 PubMedCrossRef Scattoni V, Roscigno M, Raber M, Montorsi F, Da Pozzo L, Guazzoni G et al (2003) Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 44(4):407–414. doi:10.​1016/​S0302-2838(03)00320-8 PubMedCrossRef
6.
go back to reference Pucar D, Sella T, Schoder H (2008) The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 18(1):87–97PubMedCrossRef Pucar D, Sella T, Schoder H (2008) The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 18(1):87–97PubMedCrossRef
8.
10.
go back to reference Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al (2008) The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35(1):18–23. doi:10.1007/s00259-007-0581-4 PubMedCrossRef Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al (2008) The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35(1):18–23. doi:10.​1007/​s00259-007-0581-4 PubMedCrossRef
12.
go back to reference Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K et al (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100(4):786–793. doi:10.1111/j.1464-410X.2007.07083.x PubMedCrossRef Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K et al (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100(4):786–793. doi:10.​1111/​j.​1464-410X.​2007.​07083.​x PubMedCrossRef
13.
go back to reference Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M et al (2007) Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52(2):423–429. doi:10.1016/j.eururo.2007.03.032 PubMedCrossRef Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M et al (2007) Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52(2):423–429. doi:10.​1016/​j.​eururo.​2007.​03.​032 PubMedCrossRef
15.
go back to reference Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S et al (2006) Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8(1):43–48. doi:10.1007/s11307-005-0023-2 PubMedCrossRef Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S et al (2006) Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8(1):43–48. doi:10.​1007/​s11307-005-0023-2 PubMedCrossRef
16.
17.
go back to reference Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, Reske SN, Neumaier B (2003) Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nucl Med (Stuttg) 42(1):25–30 Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, Reske SN, Neumaier B (2003) Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nucl Med (Stuttg) 42(1):25–30
18.
go back to reference Fichtner J (2006) PSA recurrence following radical prostatectomy and radiotherapy. Urologe A Fichtner J (2006) PSA recurrence following radical prostatectomy and radiotherapy. Urologe A
19.
go back to reference Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974. doi:10.1016/j.ijrobp.2006.04.029 PubMed Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974. doi:10.​1016/​j.​ijrobp.​2006.​04.​029 PubMed
21.
go back to reference Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G et al (2005) Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46(10):1642–1649PubMed Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G et al (2005) Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46(10):1642–1649PubMed
22.
go back to reference Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T (2005) 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74(3):214–220. doi:10.1159/000083551 PubMedCrossRef Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T (2005) 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74(3):214–220. doi:10.​1159/​000083551 PubMedCrossRef
23.
go back to reference Heijmink SW, Scheenen TW, Futterer JJ, Klomp DW, Heesakkers RA, Hulsbergen-van de Kaa CA et al (2007) Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol 42(6):420–427. doi:10.1097/01.rli.0000262759.46364.50 PubMedCrossRef Heijmink SW, Scheenen TW, Futterer JJ, Klomp DW, Heesakkers RA, Hulsbergen-van de Kaa CA et al (2007) Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol 42(6):420–427. doi:10.​1097/​01.​rli.​0000262759.​46364.​50 PubMedCrossRef
Metadata
Title
[11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
Authors
Ludwig Rinnab
Joerg Simon
Richard E. Hautmann
M. V. Cronauer
Kathrin Hohl
Andreas K. Buck
Sven N. Reske
Felix M. Mottaghy
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 5/2009
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-009-0371-7

Other articles of this Issue 5/2009

World Journal of Urology 5/2009 Go to the issue